Chinook Therapeutics, Inc. KDNY
Set alert
40.39 +40.39 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 2.71B
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -11.37
- Beta
- 0.68
- Short ratio
- 1.24
- Inst. own
- 96.29%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2023
- 50-d avg
- 29.15
- 200-d avg
- 24.27
- 1y target
- 39.30
Analyst view
Consensus: buy
Buy
Price target (mean) 39.30 -2.7% downside
Now 40.39
- Target (low)
- 30.00
- Target (mean)
- 39.30
- Target (high)
- 47.00
Recommendation trend
- 1 month ago 12
- 2 months ago 12
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.81 | -0.90 – -0.68 | -0.61 | -32.8% | 240.00K | -42.6% | 10 |
| Next quarter | -0.81 | -0.92 – -0.68 | -0.83 | +2.4% | 250.00K | +150.0% | 10 |
| Current year | -3.21 | -3.51 – -2.88 | -2.92 | -9.9% | 2.84M | -53.7% | 11 |
| Next year | -3.45 | -3.77 – -2.81 | -3.21 | -7.5% | 13.02M | +358.5% | 11 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 21, 2023 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Jun 14, 2023 | Evercore ISI Group | Downgrade | Outperform | In-Line |
| Jun 13, 2023 | Stifel | Downgrade | Buy | Hold |
| Jun 13, 2023 | SVB Leerink | Downgrade | Outperform | Market Perform |
| Jun 13, 2023 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Jun 12, 2023 | Cantor Fitzgerald | Downgrade | Overweight | Neutral |
| Jun 12, 2023 | Guggenheim | Downgrade | Buy | Neutral |
| Jun 12, 2023 | William Blair | Downgrade | Outperform | Market Perform |
| May 17, 2023 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| May 10, 2023 | Wedbush | Reiterated | — | Outperform |
| May 2, 2023 | Cantor Fitzgerald | Reiterated | — | Overweight |
| May 2, 2023 | Guggenheim | Maintained | — | Buy |
| Mar 6, 2023 | Piper Sandler | Initiated | — | Overweight |
| Mar 1, 2023 | Guggenheim | Initiated | — | Buy |
| Feb 28, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Feb 28, 2023 | Oppenheimer | Maintained | — | Outperform |
| Feb 21, 2023 | Oppenheimer | Maintained | — | Outperform |
| Dec 22, 2022 | Stifel | Maintained | — | Buy |
| Dec 5, 2022 | Wells Fargo | Initiated | — | Overweight |
| Aug 19, 2022 | Stifel | Initiated | — | Buy |
| Aug 15, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| May 23, 2022 | SVB Leerink | Maintained | — | Outperform |
| Jan 6, 2021 | Wedbush | Initiated | — | Outperform |
| Dec 10, 2020 | Cantor Fitzgerald | Initiated | — | Overweight |